10+ can't-miss Houston business and innovation events for May

where to be

Check out these conferences, pitch competitions, networking, and more in the month of May. Photo via Getty Images

It's time to look at what's on the agenda for May for Houston innovators — from pitch competitions to networking events.

Here's a roundup of events not to miss this month. Mark your calendars and register accordingly.

Note: This post might be updated to add more events.

May 1-4 — Offshore Technology Conference

Since 1969, OTC has served as a central hub convening the best and brightest minds in the world to share ideas, and innovations and discuss, debate, and build consensus around the most pressing topics facing the offshore energy sector.

The event is Monday, May 1, to Thursday, May 4, at NRG Park. Click here to register.

May 2 — EDGE Technology Showcase 2023: Delivering the Future

Oceanit’s 2023 EDGE Technology Showcase will run alongside Houston's Offshore Technology Conference, the Oceanit EDGE Technology Showcase event will feature technologies that are delivering the future, from deep sea to deep space — from disruptive innovations to scalable turnkey solutions.

The event is Tuesday, May 2, from 5:30 to 8:30 pm, at 1940 Air Terminal Museum. Click here to register.

May 3 — Women, Wine & Web Design - Houston

Create a web page, enjoy some wine, and network with like-minded Houston area women.

The event is Wednesday, May 3, from 5:30 to 8:30 pm, at Improving (10111 Richmond Ave.). Click here to register.

May 10 — Energy 2.0 UN-Conference - NetZero: A Race We Can All Win

Energy 2.0 is the UNconference where we celebrate diverse perspectives, technologies, and people driving the energy transition forward.

The event is Wednesday, May 10, from 8 am to 5 pm, at Woodside Energy (1500 Post Oak Blvd.). Click here to register.

May 11 — Investor Studio Series Dream Big Ventures x Ion

Hear from experts Staci Latoison, founder of Dream Big Ventures; Ramona Ortega, founder and CEO of WealthBuild.ai; and Nan Almodovar, CEO & broker.

The event is Thursday, May 11, from 5 to 7 pm, at the Ion. Click here to register.

May 11-13 — Rice Business Plan Competition

With access to mentors, real-world experience and investment opportunities, the Rice Business Plan Competition helps student founders stay on target and realize their potential. Click here to see the 2023 teams.

The event is Thursday, May 11, to Saturday, May 13, at Rice University. Click here to register.

May 12 — Linkedin Profile Refresh Workshop

This event is not just about learning new tips and tricks; it's about putting them into practice right then and there.

During the workshop, you'll have the opportunity to work on your LinkedIn profile in real-time, making changes and optimizing it for more visibility and opportunities.

The event is Friday, May 12, from 8:30 to 10:30 am, at the Ion. Click here to register.

May 17 — Engage VC: Scale Venture Partners

Alex Niehenke, Partner at Scale Venture Partners is coming to Houston and will be featured in our fireside chat moderated by Emily Hak, Managing Director, Private Capital Markets at Insperity.

The event is Wednesday, May 17, from 8:30 to 10:30 am, at the Ion. Click here to register.

May 17-19: Ion Activation Festival

Ion District is celebrating its second annual festival of innovation in Houston, known as Activation Festival which will feature:

  • A multi-day showcase of Ion District + Ion and its innovation ecosystem partners
  • An array of futuristic activations and programs alongside a lineup of engaging keynote speakers and experiences
  • A community-wide block party Friday to celebrate the heart of Houston's new innovation district

The event is Wednesday, May 17, to Friday, May 19, at The Ion. Click here to register.

May 18 — Softeq Venture Studio Houston Investor Demo Day: H1 2023 Cohort

At the Houston Investor Demo Day, founders will give their 3-minute pitch, followed by a networking session where you may get a demo of their product and ask any questions. We need you there to evaluate them for investment and give them feedback! Afterward, happy hour and dinner.

The event is Thursday, May 18, from 3 to 7 pm, at Fleming's Steakhouse (CityCentre). Click here to register.

May 23 — Houston Veterans In Residence Showcase

Bunker Labs’ Veterans in Residence Showcase is a nationwide event, celebrating our program participants as they have completed Bunker Labs' six month Veterans in Residence Program.

The event is Tuesday, May 23, from 6 to 8 pm, at Impact Hub Houston. Click here to register.

May 25 — Greentown Houston + BCG X Pitch Day

Join Greentown Houston and BCG X for a pitch competition featuring Greentown startups that are raising their pre-seed and seed rounds to grow their networks and scale their cutting-edge climatetech solutions. The winners will walk away with a total of $10,000 in cash prizes and services support from BCG X. We will also have a Fan Favorite prize, sponsored by O'Melveny who will provide in-kind service in the form of 5 hours of virtual 1:1 office consult on general corporate matters.

The event is Thursday, May 25, from 3:30 to 7:30 pm, at Greentown Houston. Click here to register.

May 30-31 — Women in Tech Texas

Discover the technologies in today's quickly changing world and learn new forward-thinking concepts in business and the workforce that will radically change our future. Join over 1,000 leading women in technology and diversity champions driving the innovation revolution to pioneer the future of technology and business.

The event is Tuesday, May 30, to Wednesday, May 31, at the Hyatt Regency. Click here to register.

May 31 — Demystifying Startup Impact Investing: SWAN Impact Network

SWAN Impact Network is joining the startup ecosystem in Houston. Join the organization for a panel with local thought leaders on "Demystifying Startup Impact Investing” and a time for networking over light bites and drinks. SWAN is an angel network whose members put their money to work to make a difference by enabling creative entrepreneurs with solid plans for financial success to address the world’s most pressing problems.

The event is Wednesday, May 31, from 6 to 7:30 pm, at Ion Houston. Click here to register.

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings